Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33683917/
doi: 10.1200/JCO.20.03433. Online ahead of print. 1 The University of Texas MD Anderson Cancer Center, Houston, TX. 2 Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland. 3 Levine Cancer Institute, Atrium Health, Charlotte, NC. 4 Onco-Hematology Division, European Institute of Oncology IRCCS, Milan, Italy. 5 Department of Health Sciences, University of Milan, Milan, Italy.
-
Mark FeslerApril 25, 2021In cross trial comparison this pi3k inhibitor appears to have less toxicity than its predecessors ...will be nice to see if randomized comparative data emerged to prove this